FOUNDATION FOR THE - Key Persons
Job Titles:
- Director, Strategic Alliances and Advancement
Job Titles:
- Project Manager, Metabolic Disorders
Job Titles:
- Scientific Project Manager
Job Titles:
- P.M.P., ITIL / Project Manager, Neuroscience
Job Titles:
- Meetings and Events Planner
Job Titles:
- Honorary Director
- Ann Lurie President
Ms. Lurie administers the Ann and Robert H. Lurie Foundation, a private philanthropic foundation in Chicago. While supporting charitable endeavors, she developed an interest in funding medical treatment, research, education and prevention. In 1995, Ms. Lurie established Lurie Investments, Inc. (now Lurie Holdings) to administer and manage her investment portfolio with a concentration on the convergence of technology and the life sciences. Investments have focused on the miniaturization of technology from micro to MEMS to nanotechnology and applications to health care. She founded and served as president of Africa Infectious Disease Village Clinics, Inc., a public charity focused on providing free quality medical care and public health services to rural communities in southeastern Kenya until its closing in late 2012. In 2013, Ms. Lurie funded the Lurie Prize in Biomedical Sciences, awarded annually by the FNIH to an outstanding young biomedical scientist. She earned a Bachelor of Science degree in Nursing from the University of Florida, and in 2010, was appointed Adjunct Assistant Professor, Preventive Medicine, at Northwestern University Feinberg School of Medicine. She holds the honorary Doctor of Laws degree from University of Michigan, the Doctor of Public Service from University of Florida and the Doctor of Humane Letters from Erikson Institute.
Job Titles:
- Scientific Project Manager, Inflammation and Immunity
Job Titles:
- Senior Project Manager, Research Partnerships
Job Titles:
- Strategic Alliances Officer
Job Titles:
- Scientific Program Manager, Policy Lead for Gene Drive Research
Job Titles:
- Deputy General Counsel
- Vice President
Job Titles:
- Associate Vice - President, Research Partnerships
Job Titles:
- Chairman
- President and Chief Executive Officer, Dame Jillian & Dr. Arthur M. Sackler Foundation for the Arts, Sciences & Humanities
- Trustee of Tufts University
Dame Jillian Sackler is Chairman Emerita and Trustee of the Foreign Policy Association. She is a Trustee of the Foundation for the National Institutes of Health and the Friends of the Mexican Development Foundation. She is the Honorary Director of the Arthur M. Sackler Museum of Art and Archaeology at Peking University in Beijing, China.
Dame Sackler has served as a Trustee of Tufts University, American Film Institute, Metropolitan Opera, New York City Ballet, and Royal Academy of Arts. She is an alumni member of the Rockefeller University Council, the Trustee Council of the National Gallery of Art, and the Smithsonian National Board. She served as International Chairman for the Edinburgh Festival Committee and on the American Committee of UNICEF.
Dame Sackler received the China Institute Blue Cloud Award 2018; Foreign Policy Association Medal 2014; Royal Academy of Arts Benjamin West Award (Anglo-American Friendship) 2009; The National Academy of Sciences Einstein Award 2005; Smithsonian Institution Benefactor of the Year Award 1993; Hahnemann University President's Award for Contributions to the Arts 1985. In 1994, she became Dame of Malta with Crown, and in 2005, was awarded a D.B.E. (Dame of the British Empire).
Job Titles:
- Scientific Program Manager, Technical Lead for Gene Drive Research
Job Titles:
- Scientific Program Manager, Vaccine Discovery and Development
Job Titles:
- Chief Growth and Innovation Officer
Job Titles:
- Executive Vice - President, Strategy and Business Development
David Wholley assumed the position as Executive Vice-President, Strategy and Business Development in May 2022. He served as the Interim President and Executive Director from September 2021 until May 2022, as the organization transitioned to new leadership. Before that, he managed the Research Partnerships Division of the Foundation, which is responsible for major research collaborations including the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), Accelerating Medicines Partnership® Program (AMP®), the Biomarkers Consortium, the LungMAP precision medicine trial in lung cancer, and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Prior to joining the Foundation in 2006, Mr. Wholley's career spanned nearly 25 years in healthcare technology business management, including extensive experience in product development, sales, marketing, corporate strategy, and partnership and project development. Mr. Wholley has held senior management roles in several venture-funded technology startup companies, including head of Global Marketing and Development for First Genetic Trust, Inc., which developed software for large-scale collaborative genetic research and personalized medicine. During a 16-year career at IBM, he co-led the corporate strategy team that guided IBM's formation of its Life Sciences industry organization. Mr. Wholley holds an M.Phil. from Rutgers University and a Certificate in Business Administration from the Stern School of Business at New York University.
Donald Hill joined the FNIH in August 2017 as the Chief Financial Officer of the Foundation. He brings more than 30 years of financial experience with for-profit and not-for-profit organizations. His experience includes CFO roles with Project HOPE, a global health education and humanitarian organization, and Metabolex (CymaBay Therapeutics), a biopharmaceutical company focused on the discovery and development of new medicines for the treatment of metabolic diseases. His career also includes more than 20 years at Merck & Co., in various Finance and Corporate Development roles. Additionally, he worked with Amneal Enterprises and its associated portfolio companies.
He received his M.S. in Finance and Applied Economics from the Sloan School of Management at the Massachusetts Institute of Technology and his B.A. in Political Economy from the University of California, Berkeley. He also holds the Chartered Financial Analyst (CFA) designation.
Job Titles:
- Retired Chairman and Chief Executive Officer, Glaxo Inc
Dr. Charles A. Sanders is the former Chairman and CEO of Glaxo Inc., and a former member of the Board of Glaxo PLC. Before joining Glaxo, Dr. Sanders spent eight years with Squibb Corp., where he held several posts, including Vice Chairman, Chief Executive Officer of the Science and Technology Group, and Chairman of the Science and Technology Committee of the Board.
Previously, Dr. Sanders was General Director of Massachusetts General Hospital in Boston and Professor of Medicine at Harvard Medical School. Dr. Sanders is a member of the Institute of Medicine of the National Academy of Sciences, a member of the Board of Trustees of the Center for Strategic and International Studies, Chairman Emeritus and Board Member of Project HOPE, and a member of multiple corporate boards. He is past chairman of the New York Academy of Sciences (NYAS), the Commonwealth Fund, and the Overseers Committee to Visit the Harvard Medical School. A native of Dallas, Dr. Sanders is a graduate of Southwestern Medical College of the University of Texas. Dr. Sanders and his wife, Ann, live in Durham, North Carolina.
Job Titles:
- President
- Professor Emeritus, Johns Hopkins University
Dr. Elias Zerhouni was most recently the President, Global Research & Development, and a member of the Executive Committee for Sanofi from January 2011 to July 2018.
Dr. Zerhouni's academic career was spent at the Johns Hopkins University and Hospital where he was professor of Radiology and Biomedical Engineering and senior adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research, and Executive Vice Dean of the School of Medicine from 1996 to 2002, before his appointment as Director of the National Institutes of Health from 2002 to 2008.
In 2009, President Obama appointed Dr. Zerhouni as one of the first presidential U.S. science envoys.
Dr. Zerhouni also served as senior fellow to the Bill and Melinda Gates foundation from 2009 to 2010. He authored more than 200 scientific publications and is a member of the U.S. National Academy of Medicine and the U.S. National Academy of Engineering.
Job Titles:
- Founder and Chairperson of Friends
Dr. Ellen V. Sigal, Ph.D., is the founder and Chairperson of Friends of Cancer Research, a Washington, D.C.-based not-for-profit organization dedicated to accelerating the nation's progress toward cancer prevention and treatment. The organization mobilizes public support for cancer research funding and providing education on key public policy issues. Dr. Sigal also holds leadership positions within a broad range of cancer advocacy and public policy organizations, including Duke University's Comprehensive Cancer Center, the Johns Hopkins Cancer Center Advisory Council, the Foundation for the National Institutes of Health, the American Association for Cancer Research (AACR), and the American Cancer Society. Dr. Sigal serves on the Board of Scientific Advisors for the National Cancer Institute and, most recently, was named to the National Institute of Health Director's Council of Public Representatives.
In her more than twenty years of commitment to advancing the war on cancer, Dr. Sigal has served in numerous critical public positions. Dr. Sigal was a Presidential Appointee to the National Cancer Advisory Board from 1992-1998, where she chaired the Budget and Planning Committee, which oversees the federal cancer budget. Additionally, Dr. Sigal also serves on the National Dialogue on Cancer's research advisory panel and previously held leadership positions with the Foundation for the American Society of Clinical Oncology.
In 1998, Dr. Sigal was named Vice Chairman of the Board of The March - a national grassroots advocacy group that brought thousands of volunteers to Washington to liaise with Congress and set a new advocacy agenda for cancer research and treatment. Dr. Sigal has also been instrumental in harnessing the energies of Hollywood on behalf of cancer research-serving as President of The Creative Community Task Force for Cancer Research.
Prior to her work in cancer research advocacy, Dr. Sigal enjoyed a highly successful and influential business career in commercial real estate. Her firm, Sigal Development, financed and developed major projects throughout the Washington and mid-Atlantic region-a portfolio in excess of one billion dollars. For her efforts on behalf of cancer research advocacy, Dr. Sigal received the 1998 American Association for Cancer Research National Leadership Award, the 1999 Sidney Kimmel Cancer Center National Leadership Award, and the 2002 American Society of Clinical Oncology Special Recognition Award.
Dr. Sigal received her Ph.D. from Rutgers University in Russian History.
Job Titles:
- Founder and Chairman of Novalis LifeSciences LLC
Dr. Marijn Dekkers is currently the founder and chairman of Novalis LifeSciences LLC, an investment and advisory firm for the life science industry. He is also the former Chairman of Unilever.
From 2010-2016, Dr. Dekkers served as Bayer AG's CEO. He was the first Bayer CEO to be appointed from outside the company. During his tenure, Bayer acquired the consumer care business of Merck & Co., Inc., floated the material science subgroup on the stock market under the name "Covestro," and systematically focused on the life sciences businesses. Under Dr. Dekkers' leadership, Bayer's previous structure - comprising a strategic management holding company and operational subgroups - was replaced by an integrated organization under the umbrella of the Bayer brand. While there, he served for two years as President of the German Chemical Industry Association (VCI), Frankfurt.
From 2002-2009, Dr. Dekkers served as CEO of Thermo Fisher Scientific (he was COO from 2000-2002). As CEO of Thermo, he initiated extensive restructuring measures, divesting various organizational units, and strengthening the company's core business by means of targeted acquisitions, including the purchase in 2006 of the significantly larger laboratory consumables supplier Fisher Scientific. This created a global life sciences company which now employs 55,000 people and generates annual sales of $18 billion.
Dr. Dekkers began his career in 1985 as a research scientist at General Electric, gaining experience in various units of the company before joining Honeywell International in 1995.
Dr. Dekkers received his M.S. and Ph.D. in Chemical Engineering from the University of Eindhoven and his B.S. in Chemistry from the Radboud University, both in The Netherlands. He holds dual U.S. and Dutch citizenships.
Job Titles:
- Vice Chairman
- Distinguished Service Professor of Neuroscience
Dr. Solomon H. Snyder is a distinguished service professor of Neuroscience, Pharmacology, and Psychiatry at the Johns Hopkins University School of Medicine. He is the founder of the Solomon H. Snyder Department of Neuroscience and served as its director from 1980 to 2006. He is world-renowned for his pioneering research in the identification of receptors for neurotransmitters and drugs and the elucidation of the actions of psychotropic agents.
Dr. Snyder completed his undergraduate work at Georgetown College and received his M.D. from the Georgetown Medical School. After further studies at the National Institutes of Health, he completed a residency in psychiatry at Johns Hopkins.
Among dozens of professional and academic honors, Dr. Snyder has received the U.S. National Academy of Science Award in Neuroscience, the Albany Prize in Medicine, the National Medal of Science, the Wolf Foundation Prize in Medicine, and the Albert Lasker Award for Basic Biomedical Research. He holds Honorary Doctor of Science degrees from Northwestern University, Georgetown University, Ben Gurion University, and the University of Maryland, among others.
Over the course of his distinguished career, he has authored or co-authored more than 1,000 peer-reviewed publications and seven books. He currently serves as Associate Editor of the Proceedings of the National Academy of Sciences of the U.S., and is a member of the United States National Academy of Sciences and a Fellow of the American Philosophical Society and the American Academy of Arts and Sciences.
Job Titles:
- Professor, President and CEO Emeritus, and Honorary Fellow, the Jackson Laboratory
- Professor, President Emeritus
Dr. Edison Liu is Professor, President Emeritus, and Honorary Fellow of The Jackson Laboratory (JAX), an independent, not-for-profit organization focusing on mammalian genetics research, in order to advance human health. Between 2012 and 2021, he led JAX through a growth phase that doubled revenues and staff, quintupled the endowment, and expanded JAX's footprint throughout the US and in Asia. Previously, Dr. Liu was the founding Executive Director of the Genome Institute of Singapore that established Singapore as a key player in functional genomics. At that time, he was also Chairman of the Health Sciences Authority, which is Singapore's equivalent of the FDA, and the President of the Human Genome Organization (HUGO). Prior to moving to Singapore in 2001, Dr. Liu was the scientific director of the National Cancer Institute's then Division of Clinical Sciences in Bethesda, Maryland. Dr. Liu's research is focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes and deciphering the dynamics of gene regulation on a genomic scale. He has authored over 320 scientific papers and reviews and co-authored two books. In his spare time, he pursues jazz piano and composition and writes for the lay public on science, medicine, and society.
Job Titles:
- Special Project Associate and Archivist
Job Titles:
- Scientific Project Manager, Neuroscience
Job Titles:
- President and Chief Operating Officer of Beacon Capital Partners
Fred Seigel is President and Chief Operating Officer of Beacon Capital Partners and is based in Boston. He joined Beacon in 2001. Previously, Mr. Seigel was Managing Director of Latona Associates, Inc., a private merchant bank. Prior to that, Mr. Seigel spent six years as President and Director of Energy Capital Partners, a company he founded that specialized in financing energy projects throughout the U.S. Mr. Seigel is a member of The Real Estate Roundtable, and also serves on the Board of Directors of the Edward M. Kennedy Institute for the United States Senate and the Board of Directors of Camp Harbor View. He holds a Bachelor of Arts from New England College.
Job Titles:
- Distinguished Fellow of the American Psychiatric Association
Throughout her career in medicine, Dr. Freda Lewis-Hall has been on the frontlines of health care as a clinician, educator, researcher, and leader in the biopharmaceuticals and life sciences industries. She served as Pfizer Inc.'s Chief Medical Officer and Executive Vice President until the end of 2018 and as Chief Patient Officer and Executive Vice President during 2019. In these roles, Dr. Lewis-Hall expanded outreach to patients, reshaped the focus on patient engagement and inclusion, improved health information and education, and amplified the voice of the patient within company culture and decision-making. She was responsible for the safe, effective, and appropriate use of Pfizer medicines and vaccines.
Before joining Pfizer, Dr. Lewis-Hall held senior leadership positions of Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals; Senior Vice President, US Pharmaceuticals at Bristol Myers Squibb; Vice President, Research and Development, Product Development at Pharmacia Corporation; and Product Team Leader and Director at Eli Lilly and Company.
Dr. Lewis-Hall currently serves on the Board of Fellows of The Harvard Medical School, the Board of Advisors of the Dell Medical School, and the Board of Governors for the Patient-Centered Outcomes Research Institute. She currently serves on the corporate boards of Milliken and Company, a global diversified industrial manufacturer; 1Life Healthcare, Inc., a health services company; Exact Sciences, Inc., a molecular diagnostics company; and SpringWorks Therapeutics, a biopharmaceutical company.
Prior to joining the biopharmaceutical industry, Dr. Lewis-Hall served as vice chairperson and associate professor in the Department of Psychiatry at Howard University College of Medicine and was an advisor to the National Institute of Mental Health. She earned a B.A. in Natural Sciences from The Johns Hopkins University and an M.D. from Howard University College of Medicine. She launched her medical career as a practicing physician and then focused her academic research on the effects of health care disparities and the impact of mental illness on families and communities.
Dr. Lewis-Hall is a Distinguished Fellow of the American Psychiatric Association and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. She is a frequent speaker on issues such as improving patient safety and health outcomes, reducing stigma and health care disparities, women's health, public health, corporate leadership, and diversity. Dr. Lewis-Hall is an accomplished developer of consumer education and medical outreach programs, including national television and radio shows such as segments on Dr. Phil, The Doctors, THE REAL, TEDMed, The Urban Health Report, and multiple online sites.
Job Titles:
- Member of the National Academy of Medicine
- Professor of Computational Medicine & Bioinformatics
Job Titles:
- Scientific Project Manager
Job Titles:
- Distinguished University Professor, University of Michigan
Dr. Gilbert Omenn is the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health, and Founding Director of the Center for Computational Medicine & Bioinformatics at the University of Michigan, Ann Arbor. His research is focused on proteo-genomics and bioinformatics of cancers. He led the global Human Proteome Project (www.hupo.org) for the past decade. He previously worked on biochemical genetics of the brain, cancer prevention, health promotion and disease prevention for older adults, and science and health policy. He is an author of 657 publications with 43,621 citations/h-index 87 and editor/author of 18 books.
He was a Research Associate with Christian B. Anfinsen at the National Institute of Arthritis and Metabolic Diseases (NIAMD); a Howard Hughes Medical Institute Investigator at the University of Washington (UW); and a member of the National Cancer Advisory Board; the National Heart, Lung and Blood Institute Council, the Society of Fellows of the National Center for Minority Health & Health Disparities, and the Scientific Management Review Committee for the National Institutes of Health. He was Dean of the School of Public Health & Community Medicine at the UW and Executive Vice-President for Medical Affairs and CEO of the Health System at the University of Michigan. He served as a White House Fellow at the U.S. Atomic Energy Commission, Associate Director of the White House Office of Science & Technology Policy and the Office of Management & Budget, and President of the American Association for the Advancement of Science. In the 1990s, he chaired the Presidential/Congressional Commission on Risk Assessment & Risk Management. He served on the boards of Amgen, Inc. and Rohm & Haas Company. He currently serves on boards of the Foundation for the National Institutes of Health, Hastings Center for Bioethics, the Center for Public Integrity, the Weizmann Institute of Science, and biotech firms.
Job Titles:
- Director, Strategic Alliances and Advancement
Job Titles:
- Vice Chairman, Goldman Sachs & Company Adjunct Professor, University of Virginia
Mr. Donovan has worked in investment banking, investment management and corporate strategy for nearly three decades. He is Vice Chairman of Global Client Coverage at Goldman Sachs, a firm he joined in 1993 and has served in a variety of positions. Mr. Donovan is also an Adjunct Professor at the University of Virginia. Mr. Donovan served on the Board of Trustees of the Dana-Farber Cancer Institute, was a member of The Lank Center for Genitourinary Oncology, and established the Jim Donovan Fund for Prostate Cancer Research at Dana-Farber in 2008, in honor of a friend who died of cancer. Mr. Donovan also serves on the Board of Trustees of the National Cathedral School.
Mr. Donovan earned his B.S. degree in Chemical Engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School in 1989. He earned his J.D. from Harvard Law School in 1993. Mr. Donovan lives with two daughters, two sons and his mother in Virginia. An avid runner, he participates in road races to raise money for cancer prevention and treatment.
Job Titles:
- Director, Inflammation and Immunity
Job Titles:
- Associate Vice President of Meetings and Events
Job Titles:
- Meetings and Events Coordinator
Job Titles:
- Scientific Project Manager, Cancer
Job Titles:
- Senior Advancement Officer, Major and Legacy Giving
Job Titles:
- Meetings and Events Coordinator
Job Titles:
- Senior Project Manager, Inflammation & Immunity
Job Titles:
- Executive Chairman & Founder, Alexandria Real Estate Equities, Inc. / Alexandria Venture Investments
Joel S. Marcus, JD, CPA, is Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE: ARE), the REIT that pioneered life science real estate from a specialty niche to a mainstream asset class. Today, it is the preeminent and longest-tenured owner, operator, and developer uniquely focused on collaborative life science, agtech, and technology campuses in AAA innovation clusters. Since co-founding the company in 1994, as a garage startup with $19 million in Series A capital and a mission to advance human health, he has led the remarkable growth of Alexandria into an S&P 500 company that as of December 31, 2021, has a total market capitalization of $44.0 billion, and a total equity capitalization of $35.2 billion, ranking it among the top 10% of all publicly traded U.S. REITs by equity capitalization. Alexandria, which celebrates its 25th anniversary as a New York Stock Exchange listed company in May 2022, has a total shareholder return exceeding 2,500% as of December 31, 2021.
Mr. Marcus also founded and continues to lead Alexandria Venture Investments, the company's strategic venture capital platform. Since its inception in 1996, it has strategically invested in disruptive life science, agrifoodtech, climate innovation, and technology companies advancing transformative new modalities and platforms to meaningfully improve human health. With nearly $2 billion in carrying value, Alexandria Venture Investments has been recognized by Silicon Valley Bank as the #1 most active corporate venture capital investor in biopharma by new deal volume for five consecutive years and by AgFunder as one of the top five most active U.S. agrifoodtech investors for the second consecutive year.
Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions with special expertise in the biopharmaceutical industry. He serves on the boards of directors of several public and private companies, including Applied Therapeutics, Inc. (NASDAQ: APLT), Frequency Therapeutics, Inc. (NASDAQ: FREQ), Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), and MeiraGTx Holdings plc (NASDAQ: MGTX). In addition to the FNIH, Mr. Marcus serves on the boards of several non-profit organizations, including the Emily Krzyzewski Center, the National Medal of Honor Museum, the Navy SEAL Foundation, the Parker Institute for Cancer Immunotherapy, and the 9/11 Memorial & Museum. He received his undergraduate and Juris Doctor degrees from the University of California, Los Angeles.
Job Titles:
- Vice President, Research Partnerships
Job Titles:
- Director, Kovler Foundation Director Emeritus, Sasha Bruce Youthwork, Inc
Dr. Kovler, a psychotherapist in private practice for more than 30 years, provides individual, family, and couples counseling to adults and adolescents. Dr. Kovler is a Director of the Kovler Foundation, which supports scientific and humanitarian programs. Additionally, she is a Board member at DC Prep, a group of charter elementary and middle schools that work to increase the number of students from underserved communities who succeed in competitive high schools and colleges. Dr. Kovler has worked as a consultant to various government agencies, including the State Department, Treasury Department, Secret Service, and the White House. In the Washington, D.C., area, she has served as a consultant to several schools and corporations. Dr. Kovler earned a B.A. from Stanford University, an MSW from the University of California, Berkley, and a Ph.D. from Catholic University.
Job Titles:
- Chief Executive Officer
- CEO, Foundation for the National Institutes of Health
- FNIH As CEO
Dr. Gerberding joined the FNIH as CEO on May 16, 2022. She served before that as chief Patient Officer and Executive Vice President, Population Health & Sustainability, at Merck & Co., Inc. She was responsible for patient engagement, corporate social responsibility, Environmental/Social/Governance issues, and other functions. Formerly, Dr. Gerberding oversaw Global Public Policy and Strategic Communications for the company. She joined Merck in 2010 as President of Merck Vaccines and was instrumental in increasing access to the company's vaccines to people around the world.
Dr. Gerberding joined the FNIH as CEO on May 16, 2022. She served before that as Chief Patient Officer and Executive Vice President, Population Health & Sustainability, at Merck & Co., Inc., where she was responsible for patient engagement, corporate social responsibility, Environmental/Social/Governance issues, and other functions. Formerly, Dr. Gerberding oversaw Global Public Policy and Strategic Communications for the company. She joined Merck in 2010 as President of Merck Vaccines and was instrumental in increasing access to the company's vaccines to people around the world.
Previously, Dr. Gerberding was Director of the U.S. Centers for Disease Control and Prevention (CDC), where she led the agency through 40 emergency responses to public health crises, including the SARS-CoV-1 outbreak. She serves on the boards of the Mayo Clinic, National Health Council, Cerner Corporation, Case Western Reserve University, AfterNext HealthTech, and HilleVax. She also co-chairs the Center for Strategic and International Studies Commission on Strengthening America's Health Security.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University and a Master of Public Health at the University of California, Berkeley. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine.
Job Titles:
- Chief Strategic Alliances and Advancement Officer
Job Titles:
- Director of Communications
Job Titles:
- Senior Operations Officer and Facilities Manager
Job Titles:
- Associate
- Operations Officer
Job Titles:
- Senior Vice President of Operations and Legal Affairs ( General Counsel )
Kevin A. Klock joined the Foundation for the National Institutes of Health (FNIH) in October 2015. As Senior Vice President of Operations and Legal Affairs (General Counsel), he provides overall leadership of the Foundation's corporate infrastructure and legal strategy and serves as a critical thought partner to the President and entire organization. He also co-chaired Legal Tools for Pandemic Preparedness: WHO Collaborating Center Support for New Coordinating Mechanisms, high-level meetings that informed the World Health Organization and global community ahead of an historic special session of the World Health Assembly on options for a treaty or other instrument on pandemic prevention and response.
Klock was formerly Head of Governance and Assistant Secretary for Gavi, the Vaccine Alliance and Company Secretary for the Gavi Campaign. There he advised the Board on the design and management of Gavi's innovative governance model and led the governance program for its finance and debt-issuance activities, including standing-up the International Finance Facility for Immunisation (IFFIm). Prior to this he was with the National Association of Corporate Directors (NACD), which provides research and education to corporate boards.
He holds an appointment at Georgetown University as Adjunct Professor of Law and Scholar at the O'Neill Institute for National and Global Health Law, where he teaches and writes at the intersection of global health, political and corporate governance, and public-private partnerships. His scholarship has been published in the Journal for the American Medical Association (JAMA), Oxford University Press, Think Global Health of the Council on Foreign Relations, among others.
Klock received his J.D., magna cum laude, from Georgetown and is a member of the bars of the District of Columbia and the United States Supreme Court. He is a graduate of Duke University, received his M.A. from American University, and was Lord Rothermere Scholar at Oxford University.
Job Titles:
- Deputy Director
- Ex Officio Director
- Principal
- Performing the Duties of the NIH Director
Lawrence A. Tabak, D.D.S., Ph.D., is performing the duties of the Director of the National Institutes of Health (NIH), officially taking office on December 20, 2021.
Dr. Tabak has served as the Principal Deputy Director and the Deputy Ethics Counselor of NIH since August 2010. He previously served as the Acting Principal Deputy Director of NIH (2009), and prior to that as Director of the National Institute of Dental and Craniofacial Research from 2000-10.
Prior to joining NIH, Dr. Tabak was the Senior Associate Dean for Research and Professor of Dentistry and Biochemistry & Biophysics in the School of Medicine and Dentistry at the University of Rochester in New York. A former NIH MERIT recipient, Dr. Tabak's major research focus has been on the structure, biosynthesis, and function of glycoproteins. He continues work in this area, maintaining an active research laboratory within the NIH intramural program in addition to his administrative duties.
Dr. Tabak is an elected member the National Academy of Medicine (formerly IOM) of the National Academies. He received his undergraduate degree from City College of New York, his D.D.S. from Columbia University, and a Ph.D. from the University of Buffalo.
Job Titles:
- Strategic Alliances Officer
Job Titles:
- Honorary Director
- Ann Lurie President
Job Titles:
- Senior Scientific Project Manager, Metabolic Disorders
Job Titles:
- Strategic Alliances Associate
Job Titles:
- Scientific Project Manager
Job Titles:
- Strategic Alliances Officer
Job Titles:
- Program Manager, Metabolic Disorders
Job Titles:
- Advancement Associate, Data and Analytics
Job Titles:
- Director, Meetings and Events
Job Titles:
- Managing Director and Global Head, BlackRock Private Equity Partners
Mr. Russell W. Steenberg, who has more than 32 years of experience in private equity investment, is the global head of BlackRock Private Equity Partners, having joined in July 1999 as founder and head of Private Equity Partners. Prior to joining BlackRock, Mr. Steenberg was a co-founder and Managing Director of Fenway Partners, a middle-market buyout group with $1.4 billion of capital. From 1983 until joining Fenway in 1995, Mr. Steenberg was employed by AT&T Investment Management Company, where he was co-head of the AT&T Pension Fund's $3.6 billion private equity investment portfolio. In addition, Mr. Steenberg is on the Board of Advisors for the Tuck Center of Private Equity and Entrepreneurship, Tuck Board of Overseers, serves on the Board of Westfield Methodist Church, and is on the Board of Directors of the Lasker Foundation. Mr. Steenberg received his M.B.A. from the Amos Tuck School of Business at Dartmouth College, an M.P.A. from American University, and a B.A. from St. Lawrence University.
Job Titles:
- Secretary
- Director Emeritus of the Albert
Deeda Blair is a long-standing effective advocate for biomedical research. Mrs. Blair is Director Emeritus of the Albert and Mary Lasker Foundation and has worked closely with Mrs. Lasker on the Citizens Committee for the Conquest of Cancer. Together they initiated one of the most successful public health outreach campaigns ever launched: The National Campaign Against High Blood Pressure, which sought to educate the public concerning the need for blood pressure screening and involved a collaboration of federal Health Agencies, pharmaceutical companies, and the Advertising Council. Mrs. Blair has had a long-time interest in cancer research and served for more than 12 years on the Board of the American Cancer Society's Research Committee, and in the 1970s, served on the Breast Cancer Task Force of the National Cancer Institute and served on the Board of Trustees of the Scripps Research Institute.
Since 1982, Mrs. Blair has had a deep involvement in the Harvard School of Public Health, with a focus on Basic AIDS research. She is Co-Chairman of the Harvard AIDS Initiative International Advisory Council. She also serves as an Advisor to the Department of Immunology and Infectious Disease Through her time living in Asia and Europe as the wife of Ambassador William McCormick Blair, Jr., Mrs. Blair developed an abiding interest in the global approach to the prevention of infectious diseases and the development of vaccines. She worked as a longtime advisor to Sandoz/Novartis in developing academic collaborations and biotech alliances. She was a consultant to Health Care Ventures for a number of biotech companies.
Job Titles:
- Chief Executive Officer at the Center for Audit Quality
- Executive Director, Center for Audit Quality
With more than two decades of experience in law and business, Ms. Julie Bell Lindsay serves as the Chief Executive Officer at the Center for Audit Quality (CAQ), a not-for-profit, non-partisan organization that advocates on behalf of the public company auditing profession.
Prior to her time at CAQ, Ms. Lindsay served as Managing Director & Deputy Head of Global Regulatory Affairs at Citigroup Inc. and as Counsel for Hogan Lovells. In addition, among other endeavors, she served as Counsel to Commissioner Cynthia Glassman at the U.S. Securities and Exchange Commission.
Ms. Lindsay holds a B.A. in Political Science from The Ohio State University as well as a J.D. from Vanderbilt Law School.
Job Titles:
- Honorary Director
- University Distinguished Service Professor, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine
Patrick C. Walsh, M.D. has been the Professor and Director of The James Buchanan Brady Urological Institute since 1974. He is best known for his pioneering work in the development of "the anatomic approach to radical prostatectomy", which involves nerve-sparing techniques that have reduced the probability of impotence and incontinence. He has also made major contributions to the basic understanding of benign and malignant neoplasms of the prostate. Along with co-workers, he was the first to describe the 5 alpha-reductase enzyme deficiency, to develop an experimental technique for the induction of benign prostatic hyperplasia, to demonstrate the influence of reversible androgen deprivation on BPH, and to characterize hereditary prostatic cancer.
He is on the editorial board of the New England Journal of Medicine, is the editor-in-chief of Campbell's Textbook of Urology, published by W.B. Saunders, and is a member of the Institute of Medicine of the National Academy of Sciences. In 1996, Dr. Walsh received the Charles F. Kettering Medal from the General Motors Cancer Research Foundation for "the most outstanding recent contributions to the diagnosis and treatment of cancer." Together with Janet F. Worthington, he authored the best-selling books for lay people The Prostate: A Guide for Men and the Women Who Love Them, which is published by Johns Hopkins University Press (1995) and Warner Books (1997) and more recently, Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Warner Books (2001).
Job Titles:
- Chairman, Novartis Institute for Tropical Diseases
In addition to serving as Chairman of the Novartis Institute for Tropical Diseases, Dr. Herrling is also a professor of Drug Discovery at the University of Basel, Switzerland.
"Paul's expertise with tropical infectious diseases will be vital to us as we continue our relationship with the Bill and Melinda Gates Foundation and on other global health initiatives," said Charles A. Sanders, M.D., former FNIH chairman. "Bettering global health is a priority for the FNIH."
Prior to his current position, Dr. Herrling was head of both Novartis Institutes for Developing World Medical Research, supervising four institutes. In addition to the FNIH, he serves on boards of The Scripps Research Institute, University Council of the University of Basel, Scientific Advisory Committee of the Drugs for Neglected Diseases Initiative, and is Vice President of the Board of Swiss Federal Institutes of Technology. He is active as Secretary of the Board of DNDi, Drugs for Neglected Diseases in Geneva, Advisor to the Wellcome Trust. He serves on the SAB of H3D a drug discovery initiative at Cape Town University, on the Board of Neurobio in Oxford, and as Chair of the Selection Committee of the RIGHT Fund in Seoul, South Korea.
"Paul's strong global network and deep understanding of neglected diseases will make him an invaluable board member," according to Kathy Bloomgarden, FNIH board member. "He's dedicated himself to advance biomedical research and provided innovative thinking to the access to medicines debate. He will be an asset in helping to overcome some of the most challenging and integral health issues of today."
Job Titles:
- Chairman, Perspecta Trust
For more than three decades, Mr. Montrone has directed the development of a number of businesses. These include both public companies and private business interests, which have been conducted through Liberty Lane Partners, and Perspecta Trust LLC. He is presently Chairman of these entities. Mr. Montrone was the Chief Executive Officer of Fisher Scientific International Inc., from 1991 until 2006. Previously, he was the Chairman and CEO of Wheelabrator Technologies Inc., a leading environmental services company. Mr. Montrone began his career at the Pentagon, serving in the Systems Analysis Group in the Office of Secretary of Defense Robert McNamara while a Captain in the U.S. Army. Mr. Montrone was a member of President Clinton's Advisory Commission on Consumer Protection and Quality in Health Care, as well as a founder of the National Forum for Health Care Quality Measurement and Reporting. He has served on a number of corporate boards, civic committees and commissions, and not-for-profit institutions, especially The Metropolitan Opera, where he held various offices over three decades including President and CEO. He is presently on Boards of the Columbia University Graduate School of Business, the New England Conservatory and the Boston Symphony Orchestra. Mr. Montrone graduated magna cum laude from the University of Scranton in 1962 and holds a Ph.D. from Columbia University. A helicopter pilot, he is now Board Chairman of the New England Helicopter Council.
Job Titles:
- Retired Executive Vice President and Chief Scientific Officer, Johnson & Johnson
As former Chief Scientific Officer of Johnson & Johnson, Paul Stoffels spearheaded its research and product pipeline by leading teams across all sectors to set the companywide innovation agenda, discovering and developing transformational healthcare solutions. He also was responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steered the company's global public health strategy to make innovative medicines and technologies accessible in the world's most vulnerable communities and resource-poor settings.
In 2002, he joined Johnson & Johnson with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV, which helped to transform this devastating disease from a death sentence to a chronic and treatable condition. Dr. Stoffels retired from his post at Johnson & Johnson in 2021.
Dr. Stoffels studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.
Job Titles:
- Senior Accounting Manager
Job Titles:
- Vice President of Advancement
With 25 years of fundraising experience, Mr. Balthaser has held senior management positions, most recently at Independent Sector, Trust for the National Mall, American Foundation for Aids Research, New York University Child Study Center and Manhattan College. Mr. Balthaser oversees the FNIH's robust portfolio of individual donors, which for 20 years has helped advance biomedical science in support of the mission of the National Institutes of Health.
Serving in leadership positions at four colleges and universities, Mr. Balthaser led the University of Maryland's Campaign for Scholarships, a $350 million initiative supporting student financial assistance. Mr. Balthaser is a certified fundraising executive and a member of the Association of Fundraising Professionals, as well as a trustee at Alvernia University. He serves on the Boards of the Verona Parc Condominium Association and Young Moderates for America. Mr. Balthaser holds a Master's of Science in Education from the University of Pennsylvania and a Bachelor of Arts degree in English from Alvernia University.
Job Titles:
- Ex Officio Director
- Commissioner of Food
- MACC Commissioner, Food and Drug Administration
- Member of the National Academy of Medicine
Robert M. Califf, M.D., is Commissioner of Food and Drugs. President Joe Biden nominated Dr. Califf to head the U.S. Food and Drug Administration and Dr. Califf was sworn in on February 17, 2022. Previously, Dr. Califf served as Commissioner of Food and Drugs from February 2016 to January 2017. As the top official of the FDA, Dr. Califf is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health. Dr. Califf served as the FDA's Deputy Commissioner for Medical Products and Tobacco from February 2015 until his first appointment as Commissioner in February 2016.
Prior to rejoining the FDA, Dr. Califf was head of medical strategy and Senior Advisor at Alphabet Inc., contributing to strategy and policy for its health subsidiaries Verily Life Sciences and Google Health. He joined Alphabet in 2019, after serving as a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,300 publications in the peer-reviewed literature.
Dr. Califf became a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and the FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.
While at Duke, Dr. Califf led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory Coordinating Center.
Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco and a fellowship in cardiology at Duke.
Job Titles:
- Adjunct Professor of Neurology at the University of Rochester
- Adjunct Professor of Neurology, University of Rochester
Dr. Krall is Adjunct Professor of Neurology at the University of Rochester. He is a member of the Safety Board of Takeda Pharmaceuticals, is Chairman of the Board of Pierian Biosciences, and consults for a number of healthcare companies.
Former Chief Medical Officer for GlaxoSmithKline (Retired), Dr. Krall worked for four companies (Lorex Pharmaceuticals, Abbott Laboratories, Zeneca/AstraZeneca, and GlaxoSmithKline) over 25 years. His areas of expertise include the ethics of human subject experimentation, drug development, regulatory science, and the safety of medicines. Dr. Krall was a founding member of the Observational Medical Outcomes Partnership, served on its Executive Committee, and led its research subcommittee.
Dr. Krall is a graduate of Phillips Exeter Academy, holds a B.A. in Mathematics from Swarthmore College, an M.D. from the University of Pittsburgh, was a Staff Associate in the Epilepsy Branch of the National Institutes of Health, and completed his training in Neurology and a fellowship in Clinical Pharmacology at the University of Rochester.
Dr. Krall currently makes his home in Steamboat Springs, Colorado, where he serves as Chair of the Board of the Yampa Valley Community Foundation, is President of the Timbers Water and Sanitation District, and serves as advisor and ranch manager for BookTrails, a 501(c)3 literacy organization for children. Dr. Krall and his wife own and operate Off the Beaten Path, an independent bookstore, coffeehouse, and bakery café (www.steamboatbooks.com) - one of the 28 "coolest" independent bookstores in America (https://matadornetwork.com/read/28-coolest-independent-book-stores-us/).
Job Titles:
- Honorary Director
- Professor of Medicine
Dr. Thier is Professor of Medicine and Health Care Policy, Emeritus. He was with the Harvard Medical School from 1994 to 2007. Dr. Thier was President and Chief Executive Officer of Partners HealthCare System, Inc., from 1996 to 2002. Previously, he served as President of the Massachusetts General Hospital, having served the previous three years as Brandeis University's sixth president. Prior to that, he served six years as president of the Institute of Medicine of the National Academy of Sciences. Dr. Their also served 11 years as Chairman of the Department of Internal Medicine at Yale University School of Medicine, where he was Sterling Professor. He holds 16 honorary degrees and is the recipient of the UC Medal of the University of California, San Francisco. He has served as President of the American Federation of Clinical Research and Chairman of the American Board of Internal Medicine, and is a Master of the American College of Physicians, a Fellow of the American Academy of Arts and Sciences, and a member of the American Philosophical Society. Dr. Thier is a member of the Board of Overseers of Cornell University Weill Medical College and the Board of Overseers of Brandeis University Heller School for Social Policy and Management. He attended Cornell University and received his M.D. from the State University of New York at Syracuse.
Job Titles:
- Founder
- Founder and Chief Executive Officer, the Sherry Lansing Foundation
Sherry Lansing is the founder and current chair of The Sherry Lansing Foundation, a philanthropic organization focusing on cancer research, health and education. Ms. Lansing was the chair of the Motion Picture Group of Paramount Pictures from 1992 to 2005, where she oversaw the release of more than 200 films including Academy Award® winners Forrest Gump (1994), Braveheart (1995), and highest grossing movie of all time, Titanic (1997). A pioneering studio executive, Lansing is the first woman in the film industry to oversee all aspects of a studio's motion picture production.
Prior to becoming Chairman of the Motion Picture Group, Ms. Lansing headed her own production company, Lansing Productions, which produced Paramount Pictures' Indecent Proposal. Before that, during her partnership with Stanley Jaffe, formed in 1983, Jaffe/Lansing Productions produced a variety of films for Paramount, among them, The Accused, Black Rain, Fatal Attraction, Racing With the Moon and School Ties. From 1980 to 1983, Ms. Lansing served as President of Production at 20th Century Fox. She was the first woman to hold that position in the motion picture industry. Prior to joining Fox, Ms. Lansing served as Senior Vice President at Columbia Pictures.
Her distinguished career has earned her numerous honors, including the Woodrow Wilson Award for Corporate Citizenship, the Milestone Award from the Producers Guild of America, the Overcoming Obstacles Achievement Award for Business, the YWCA Silver Achievement Award, the Outstanding Woman in Business Award from the Women's Equity Action League, the Distinguished Community Service Award from Brandeis University, the Alfred P. Sloan, Jr. Memorial Award and an honorary Doctorate in Fine Arts from the American Film Institute. She was also the recipient of the Simon Wiesenthal Center Distinguished Service Award for the Performing Arts and was named the Pioneer of the Year by the Foundation of the Motion Picture Pioneers. Lansing has also received the Horatio Alger Humanitarian Award, the Big Brothers Big Sisters (L.A.) Legacy Award and the American Association of Cancer Research Public Service Award. Lansing is the first woman studio head to receive a star on the Hollywood Walk of Fame and place her hand and foot prints at Grauman's Chinese Theater.
In December 2004, Lansing was appointed to the Independent Citizens' Oversight Committee of the California Institute for Regenerative Medicine. The CIRM was established by California's groundbreaking ballot measure, Proposition 71, which provides for $3 billion in funding for embryonic stem cell research. Lansing serves as the patient advocate for Cancer, as well as the chair of the Governance Committee and co-chair of the Scientific and Medical Accountability Standards Working Group.
Lansing serves on the Executive Committee of the Board of Directors of Friends of Cancer Research and the Lasker Foundation, and as a Trustee of the American Association for Cancer Research. She continues to lend her energy and talents to such advisory boards and committees as the American Red Cross Board of Governors, the board of trustees for the Carter Center and Stop Cancer, a not-for-profit philanthropic group she founded in partnership with Dr. Armand Hammer. Lansing is also a Regent of the University of California and serves as chair of the University Health Services Committee.
Lansing graduated cum laude with a Bachelor of Science Degree from Northwestern University in 1966.
Job Titles:
- Program Manager, Neuroscience
Job Titles:
- Associate Vice - President, Research Partnerships
Job Titles:
- Senior Scientific Advisor
Mr. Mayer is the former CEO of CoGenesys Inc., a privately owned biopharmaceutical company that he co-founded in 2005 and was acquired by Teva in 2008. Prior to joining CoGenesys, Mr. Mayer was Executive Vice President and Chief Financial Officer of Human Genome Sciences, Inc. Mr. Mayer also previously served as Vice President and Chief Financial Officer of GenVec Inc., an early-stage gene-therapy company, and Vice President and Chief Financial Officer for TheraTech, Inc., a leading drug-delivery company. Mr. Mayer is a Trustee of The Landon School and of The Norwood School in Bethesda, Maryland. He has served on the NASDAQ Issuer Affairs Committee, on the Financial Accounting Standards Board Small Business Advisory Committee, and as a Director and Treasurer of the Strathmore Hall Foundation in North Bethesda, Maryland. Mr. Mayer holds a B.A. in Economics from Williams College and an M.B.A. from Stanford University.
Job Titles:
- Associate Vice President, Research Partnerships
Dr. Paul is currently the Chief Executive Officer and Chairman of the Board for Karuna Pharmaceuticals and the Venture Partner at Third Rock Ventures. He was formerly the Chief Executive Officer of Voyager Therapeutics, the Founding Director of the Helen and Robert Appel Alzheimer's Disease Research Institute and the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases, as well as a DeWitt Senior Scholar and Professor of Neuroscience (Brain and Mind Research Institute), Psychiatry and Pharmacology at Weill Cornell Medical College. Dr. Paul was also formerly the Executive Vice President of Science and Technology and President of the Lilly Research Laboratories (LRL) of Eli Lilly and Company, overseeing the development of several of Lilly's largest products including Zyprexa® and Cymbalta®. Prior to assuming his position at Lilly and Weill Cornell Medical College, Dr. Paul served as Scientific Director of the National Institute of Mental Health (NIMH/NIH) in Bethesda, Maryland.
Dr. Paul is a member of various professional and honorary societies, including Phi Eta Sigma; Alpha Epsilon Delta; Sigma Xi; Phi Beta Kappa; and the Alpha Omega Alpha Honorary Medical Society. He is the recipient of many honors and scientific recognitions, including: The Distinguished Service Medal of the United States Public Health Service (USPHS) and the Chief Scientific Officer of the Year Award. In 1997, Dr. Paul was elected to membership in the National Academy of Medicine of the National Academy of Sciences. In 2004, Dr. Paul was elected a Fellow of the American Association for the Advancement of Science (AAAS).
Dr. Paul has authored or co-authored over 500 papers and invited book chapters and was listed as one of the most highly cited scientists in the world (top 50 in Neuroscience) (1980-2000) by the Institute for Scientific Information (I.S.I.), Philadelphia, Pennsylvania. He holds 9 patents on inventions made at both NIH and Lilly. His current work has focused on the role of apoE in the pathogenesis of Alzheimer's disease. He is also a co-inventor of solanezumab, a humanized anti-Aβ monoclonal antibody currently in late-stage clinical testing by Lilly as a potential disease-modifying treatment for Alzheimer's disease. Dr. Paul is on the boards of several publicly traded and private biopharmaceutical companies, including Alnylam Pharmaceuticals, Sage Therapeutics, and the Sigma Aldrich Company, and is also a founder of Sage Therapeutics, Voyager Therapeutics, and Tal Medical, dedicated to discovering and developing novel therapeutics for neurological and psychiatric disorder.
Job Titles:
- Strategic Alliances Officer
Job Titles:
- Director, Metabolic Disorders
Job Titles:
- Scientific Project Manager, Cancer
Job Titles:
- Meetings & Events Planner ( 301 ) 496 - 8126
Job Titles:
- Senior Project Manager, Cancer
Job Titles:
- President and Co - Founder, Mindstrong Health
Dr. Tom lnsel, M.D., a psychiatrist and neuroscientist, has been a national leader in mental health research, policy, and technology. From 2002-2015, Dr. Insel served as Director of the National Institute of Mental Health (NIMH). More recently, he led the Mental Health Team at Verily (2015-2017); co-founded Mindstrong Health (2017-2019), a start-up building tools for people with serious mental illness; and served as a special advisor to California Governor Gavin Newsom (2019), helping on behavioral health issues. In 2020, he co-founded Humanest Care, a therapeutic online community for recovery. He currently serves on the boards of FNIH , Fountain House, Schaeffer Center for Health Policy, and the Steinberg Institute (Chair, 2019-2022) as well as being an advisor to several mental health start-ups (including Alto Neuroscience, Cerebral, Compass Pathways, Owl Insights, Koa Health, Valera Health). He is the author of Healing: Our Path from Mental Illness to Mental Health (Penguin Random House, 2022). With journalist co-founders, he recently launched MindSite News (www.mindsitenews.org), a non-profit digital publication focused on mental health issues. Dr. Insel is a member of the National Academy of Medicine and has received numerous national and international awards including honorary degrees in the U.S. and Europe. More info at www.thomasinselmd.com.
Job Titles:
- Assistant General Counsel
Job Titles:
- Senior Scientific Project Manager, Neuroscience